Award
National Institute on Aging RFA-RM-21-017
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures
Recipient
National Institute on Aging (NIA)
Award Amount
$914,477.00
Ceiling
$914,477.00
Awarded
July 28, 2025
Identifier
RFA-RM-21-017
This NIH grant supports the development of a smart cell drug delivery platform targeting Alzheimer's disease, aiming to improve combination therapy effectiveness and rescue failed antibody treatments through innovative cellular and in vivo testing.
Description
The project aims to develop a smart cell-based drug delivery system for Alzheimer's disease, supporting combination therapy with drugs like Aducanumab and Zagotenemab. The project involves initial testing in human and mouse cells, followed by in vivo validation in transgenic mouse models. The goal is to provide proof-of-concept for translatable drug therapy for human intervention.